Patents Assigned to Inozyme Pharma, Inc.
  • Methods of treating myointimal proliferation
    Patent number: 11364284
    Abstract: The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: June 21, 2022
    Assignees: Inozyme Pharma, Inc., Westfaelische Wilhelms-Universitaet Muenster
    Inventors: Yan Yan, Anumeha Shah, Ashmita Saigal, Herman Griffin, Susan Faas McKnight, Andre Marozsan, Kim Askew, Yvonne Nitschke, Frank Rutsch
  • Methods of treating tissue calcification
    Patent number: RE49529
    Abstract: The present invention provides a method of treating NPP1 deficiency or NPP1-associated disease such as idiopathic infantile arterial calcification (IIAC), pseudoxanthoma elasticum, vascular calcification in chronic kidney disease (VCCKD), insulin resistance, hypophosphatemic rickets, myocardial ischemia, joint calcification, angioid streaks, and ossification of the posterior longitudinal ligament of the spine. The present invention provides a method for treating tissue calcification by administering soluble NPP1 to produce a transient increase in serum pyrophosphate levels.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: May 16, 2023
    Assignee: Inozyme Pharma, Inc.
    Inventors: Anthony Quinn, Nelson Hsia, Tayeba Khan, Kim Lynette Askew, Gregory Grabowski, Zhiliang Cheng, W. Charles O'Neill